Systematic review identifies liquid biopsy biomarkers predicting recurrence in triple-negative breast cancer, suggesting effective monitoring tools.
INTRODUCTION: Triple-negative breast cancer (TNBC) is associated with high recurrence and mortality. Liquid biopsy biomarkers, such as circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and microRNAs (miRNAs), offer noninvasive tools for monitoring TNBC. METHODS: A systematic review on liquid biopsy in TNBC was conducted and analyzed using PRISMA guidelines and later assessed via the EPHPP tool. RESULTS: Across 20 studies, ctDNA was a strong predictor for poorer disease-free survival (DFS) and relapse-free survival (RFS). Other biomarkers, including cfDNA and miRNAs, also showed prognostic value. CONCLUSION: Liquid biopsy, particularly ctDNA, is a valuable predictor of TNBC recurrence, supporting noninvasive monitoring and prognosis.
No takes yet. Share an insight, caveat, or question.
Rahadiani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: